SYSTEMIC TACROLIMUS (FK-506) IS EFFECTIVE FOR THE TREATMENT OF PSORIASIS IN A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Background and Design: Fifty patients with severe recalcitrant plaque- type psoriasis were randomized to receive treatment with either oral t acrolimus (FK 506) (n=27) or placebo (n=23) for 9 weeks. The two treat ment groups were comparable with respect to baseline demographic data. The initial dose was 0.05 mg/kg per day and, in cases of insufficient efficacy, could be increased to 0.10 and 0.15 mg/kg per day at the en d of weeks 3 and 6, respectively. Treatment efficacy was based on the percentage reduction in the Psoriasis Area and Severity Index compared with baseline data. Patients were defined as responding to therapy if the percentage change in the Psoriasis Area and Severity Index from b aseline after 3, 6, and 9 weeks was 26% or greater, 45% or greater, an d 70% or greater, respectively. Safety was assessed on the basis of al l adverse events reported. Results: At the end of week 9, tacrolimus-t reated patients had a significantly greater reduction in the Psoriasis Area and Severity Index than did placebo-treated patients (tacrolimus , -83; placebo, -47; P<.02). Similar numbers of patients in both group s responded to therapy at the end of week 3, but at the end of weeks 6 and 9, more tacrolimus-treated patients responded to therapy (week 6, 12 tacrolimus- and six placebo-treated patients; week 9, 12 tacrolimu s- and three placebo-treated patients). Diarrhea, paresthesia, and ins omnia were the most frequently reported causally related adverse event s in the tacrolimus-treated group. All of the reported adverse events were mild or moderate in severity, and all resolved without a change i n study medication. Conclusion: Compared with placebo, tacrolimus is e fficacious in the treatment of recalcitrant plaque-type psoriasis.